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Abstract: Molecular mechanisms underlying the pathogenesis and progression of malignant thyroid
cancers, such as follicular thyroid carcinomas (FTCs), and how these differ from benign thyroid lesions,
are poorly understood. In this study, we employed network-based integrative analyses of FTC and
benign follicular thyroid adenoma (FTA) lesion transcriptomes to identify key genes and pathways
that differ between them. We first analysed a microarray gene expression dataset (Gene Expression
Omnibus GSE82208, n = 52) obtained from FTC and FTA tissues to identify differentially expressed
genes (DEGs). Pathway analyses of these DEGs were then performed using Gene Ontology (GO)
and Kyoto Encyclopedia of Genes and Genomes (KEGG) resources to identify potentially important
pathways, and protein-protein interactions (PPIs) were examined to identify pathway hub genes. Our data
analysis identified 598 DEGs, 133 genes with higher and 465 genes with lower expression in FTCs.
We identified four significant pathways (one carbon pool by folate, p53 signalling, progesterone-mediated
oocyte maturation signalling, and cell cycle pathways) connected to DEGs with high FTC expression;
eight pathways were connected to DEGs with lower relative FTC expression. Ten GO groups were
significantly connected with FTC-high expression DEGs and 80 with low-FTC expression DEGs.
PPI analysis then identified 12 potential hub genes based on degree and betweenness centrality;
namely, TOP2A, JUN, EGFR, CDK1, FOS, CDKN3, EZH2, TYMS, PBK, CDH1, UBE2C, and CCNB2.
Moreover, transcription factors (TFs) were identified that may underlie gene expression differences
observed between FTC and FTA, including FOXC1, GATA2, YY1, FOXL1, E2F1, NFIC, SRF, TFAP2A,
HINFP, and CREB1. We also identified microRNA (miRNAs) that may also affect transcript levels of
DEGs; these included hsa-mir-335-5p, -26b-5p, -124-3p, -16-5p, -192-5p, -1-3p, -17-5p, -92a-3p, -215-5p,
and -20a-5p. Thus, our study identified DEGs, molecular pathways, TFs, and miRNAs that reflect
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molecular mechanisms that differ between FTC and benign FTA. Given the general similarities of these
lesions and common tissue origin, some of these differences may reflect malignant progression potential,
and include useful candidate biomarkers for FTC and identifying factors important for FTC pathogenesis.
Keywords: thyroid cancer; carcinoma; protein-protein interaction; reporter transcription factors; reporter
microRNAs; molecular pathways
1. Introduction
Thyroid cancers are the most common type of endocrine malignancy, although they have a relatively
low mortality rate compared to most other common metastatic diseases. The United States had 56,460 new
diagnoses of thyroid cancer and 1780 related deaths reported in 2012 [1]. The incidence of thyroid cancers is
also rising globally at about 5% per year, although some of this increase may be due to improved detection,
and it notably affects those in the 20 to 34 year age range [2]. Thyroid cancers include several major
types, such as papillary thyroid carcinomas, medullary thyroid carcinoma, anaplastic thyroid carcinoma,
and follicular thyroid carcinomas (FTCs) [3]; FTC is one of the more aggressive types, although it accounts
for a minority (14%) of total thyroid cancers [4–6].
The causes and cellular processes underlying FTC and controlling these tumours’ behaviours are
poorly understood; accordingly, these cancers have few effective treatment options [7]. There is therefore
a great need to understand the mechanisms that drive development and progression in FTC to identify
new approaches to detection, estimate the risk of progression, and find new therapies. In addition,
differential diagnosis of FTC is problematic as it can be difficult to distinguish from follicular thyroid
adenoma (FTA), a benign and non-invasive lesion. Accordingly, there is more focus on molecular markers
that distinguish FTC and FTA (and other types of thyroid lesions). Thus, Wojtas et al. conducted a gene
expression comparison of FTC and FTA lesions which identified potential markers that can distinguish
FTC from FTA with a sensitivity and specificity of 78% and 80%, respectively [8]. We aim to also use this
dataset to identify pathways with different levels of activity in benign and aggressive thyroid tumours
(here, FTA and FTC) that may reflect important molecular mechanisms that underlie their behaviour.
For such pathway studies, our starting point is the differential expression of genes (DEGs) between
these lesions. We can then use analytic tools to study these DEGs and discover pathways, and pathway hub
genes that may affect cell functions and thereby underlie tumour morbidity, growth, and invasion [9–12].
The repertoire of candidate pathway factors can be extended using approaches such as gene ontology
analysis and protein-protein interaction (PPI) studies.
To identify such DEGs, microarray gene expression profiling is widely used [13,14], and several such
studies have been performed on thyroid cancer subtypes [15]. For example, Huang et al. [16] studied
gene expression profiles of thyroid cancers, although not functional interactions between gene products.
To better understand the underlying molecular mechanisms and identify functionally critical biomolecules,
integrative analysis within a gene network context is needed [17–20]. That may lead to candidate FTC
biomarkers (the focus of the work by Wojtas et al.), but our main interest here is to obtain key or hub genes
distinguishing malignant FTC from benign FTA, as these may be potential therapeutic targets. Such a
systems biology approach integrating statistical network and topological analyses of experimental datasets
can thus clarify disease mechanisms that are difficult to identify by other approaches [21]. Thus, we used a
systems approach (Figure 1) to identify FTC molecular signatures at the miRNA and mRNA levels (and
derived from these, the protein-protein interactions) that distinguish FTC tissue from FTA. These analyses
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should be more meaningful than a comparison between FTC with normal thyroid tissue, as the the two
tumour types are similar, while markedly differing in their potential for invasive metastasis.
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Figure 1. The multi-stage analysis methodologies employed in this study. Gene expression datasets related
to follicular thyroid carcinoma (FTC) and follicular thyroid adenoma (FTA) tissues were collected from the
NCBI Gene Expression Omnibus (NCBI-GEO) database and statistically analysed using GEO2R to identify
differential expression of genes (DEGs). Four types of functional enrichment analyses of DEGs were then
performed to identify significantly enriched pathways. Thus, we constructed protein-protein interaction
networks around DEGs topological analyses to identify putative pathways hub proteins, identified possible
micro-RNA (miRNA) and transcription factor (TF) interactors, and used Gene Ontology annotation terms
to provide pathways enrichment. TF and miRNA studies employed JASPAR and miRTarbase databases,
respectively. DEGs were integrated with those networks, and higher degree and the betweenness centrality
were used to designate TFs and miRNAs as the reporter transcriptional regulatory elements. The target
DEGs of reporter miRNAs and TFs were subjected to pathway enrichment analyses.
2. Materials and Methods
In this study, the multi-step analysis method we developed and applied is shown in Figure 1.
We statistically analysed gene expression datasets to identify the DEGs and their regulatory patterns.
We employed these DEGs to identify enriched pathways, biological processes, and annotation terms (i.e.,
Gene Ontology terms) by using functional enrichment methods. Then, to identify reporter biomolecules,
we integrated the intermediate analysis results with biomolecular networks.
2.1. Dataset Employed and Statistical Methods Used
We obtained the gene expression data of FTC and FTA (GSE82208) for our study from the NCBI Gene
Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo/) [8,22]. This dataset contains analyses
of RNA from frozen tumour tissue specimens from 27 FTC and 25 FTA lesions using Affymetrix human
genome U133 (Plus 2.0) arrays. The lesions were diagnosed histologically, many with a second diagnosis to
confirm, when paraffin embedded material was available [8]. Gene expression analysis using microarrays
is a widely used method to develop and refine the molecular determinants of disorders affecting humans.
Using these methods, we analysed the gene expression profiles of FTC and FTA. To identify the DEGs
between FTC samples and FTA, we ran t-tests using the Limma package [23]. To identify the up-regulated
genes, we used the conditions of p-value < 0.05 and logFC > 2 (FC, fold change), and for identifying the
down-regulated genes, p-value < 0.05 and logFC < −2 were used. All identified up-regulated genes and
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down-regulation genes were considered DEGs. We applied the topological and neighbourhood-based
benchmark methods to find gene-gene associations. A gene-gene network was constructed by using the
gene-gene associations, where the nodes in the network represent gene [18,24]. This network can also be
characterised as a bipartite graph. These topological and neighbourhood-based benchmark methods were
adopted from our previous studies [12].
The common neighbours are based on the Jaccard Coefficient method, where the edge prediction
score for the node pair is as [25]:
E(i, j) =
N(Gi ∩ Gj)
N(Gi ∪ Gj) (1)
where G is the set of nodes and E is the set of all edges. We used R software packages “comoR” [9] and
“POGO” [12] to cross-check the genes-diseases associations.
2.1.1. Functional Enrichment of Gene Sets
We performed gene ontology and pathway analysis on identified up-regulation genes
and down-regulation genes using DAVID bioinformatics resources (https://david-d.ncifcrf.gov/)
(version v6.8) [26] to obtain further insight into the molecular pathways that differ between FTC and FTA.
In these analyses, GO and KEGG pathway databases were used as annotation sources. Enrichment results
showing adjusted p-values < 0.05 were considered significant.
2.1.2. Construction and Analysis of Protein-Protein Interaction (PPI) Subnetworks
The PPI network was first constructed with the DEGs and analysed using STRING [27], a web-based
visualisation software resource. The constructed PPI network was represented as an undirected graph,
where nodes represent the proteins and the edges represent the interactions between the proteins.
To construct the PPI network from the STRING database (http://string-db.org) [27], we used database
data, data mined from PubMed abstract text. Co-expression, gene fusion, and neighbourhood were active
interaction sources and a combined score that was greater than 0.4 was set as the level of significance.
The PPI network was then visualised and analysed using Cytoscape (v3.5.1) [28,29]. A topological analysis
was applied to identify highly connected proteins (i.e., hub proteins) by using the Cyto-Hubba plugin [30]
where betweenness centrality and higher degree were employed. The top three modules (i.e., the three
most highly interconnected protein clusters) in the PPI subnetwork were identified using the MCODE
plug-in [30]. These modules were further analysed and characterised using enrichment analyses by
NetworkAnalyst [31]. The KEGG pathway enrichment analysis of the PPI networks involving DEGs were
performed by NetworkAnalyst [31].
2.1.3. Identifying TFs and miRNAs that Influence the Expression of Candidate Genes
To identify TFs and miRNAs that affect transcript levels around which significant changes occur at the
transcriptional level, we obtained experimentally verified TF-target genes from the JASPAR database [32]
and miRNA-target gene interactions from TarBase [33] and miRTarBase [34] by using NetworkAnalyst
tools [31] where betweenness centrality and higher degree filters were used. At the time, there were many
techniques to measure the topological properties. We used the degree centrality (DC) and betweenness
centrality (BC) to find out network’s topological properties. We can define the DC of a node v in a network
as the total number of nodes which are directly connected to node v in that network. The definition can
also be written as follows [35]:
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DC(v) = ∑
j∈G
avj
n− 1
whereas n represents total number of nodes in the network, and avj represents that the node v and the
node j are directly connected. In the case of betweenness centrality (BC), the total number of times of node
v appearing in the shortest path between other nodes is quantified. It is also defined as follows [35]:
BC(v) = ∑
i 6=j 6=v∈V
σivj
σij
where σij = total number of shortest paths from node i to node j, and σivj = total number of paths through
node v.
3. Results
3.1. Results of DEG Analyses
Transcriptomic Signatures: Differentially Expressed Genes
FTA and FTC tissue gene expression patterns were analysed using oligonucleotide microarrays from
the NCBI GEO (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE82208) [8]. Gene expression
profiling was performed in 27 malignant FTCs and 25 FTAs: 598 genes were differentially expressed
(p < 0.05,> 1.0 log2 fold change) relative to FTAs, of which 465 genes were significantly lower expression
and 133 genes were higher expression levels in FTC lesions.
3.2. Pathway and Functional Correlation Analysis
By combining large scale and state of the art transcriptome and proteome analysis, we performed
a regulatory analysis to gain further insight into the molecular pathways associated with the FTC and
predicted links to pathways that differ relative to the benign FTAs. DEGs and pathways were analysed
using KEGG pathway database (http://www.genome.jp/kegg/pathway.html) and functional annotation
tool DAVID version 6.8 (http://niaid.abcc.ncifcrf.gov) to identify overrepresented pathway groups, and it
was observed that four pathways were associated with DEGs with higher expression in FTC compared
to FTA; namely, the “one carbon pool by folate” pathway, the p53 signalling pathway, the cell cycle,
and the progesterone-mediated oocyte maturation signalling pathway. Fold enrichment, adjusted p-values,
and genes associated with these pathways are presented in Table 1 (a).
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Table 1. (a) Part A shows pathways associated with the genes showing higher expression in FTC than
FTA. This set showed an enrichment of four KEGG pathways, annotated using DAVID. Part B shows
pathways associated with genes showing lower expression levels in FTC. This set showed in an enrichment
of eight KEGG pathways using DAVID. Fold enrichment, adjusted p-values and genes associated with
these pathways are indicated. (b) Summary of reporter biomolecules (including putative hub genes, TFs,
and miRNAs) in that differ between FTC and FTA.
(a)
KEGG ID Pathway Genes in the Pathway Fold
Enrichment
Adjusted
p-Value
A.
hsa00670 One carbon pool by folate MTHFD2, TYMS, SHMT2, ALDH1L1 24 5.21E-04
hsa04115 p53 signaling pathway CDK1, CCNB2, RRM2, PMAIP1,
IGFBP3
9 2.03E-03
hsa04110 Cell cycle CDK1, MAD2L1, CCNB2, BUB1, BUB1B 5 1.77E-02
hsa04914 Progesterone-mediated
oocyte maturation
CDK1, MAD2L1, CCNB2, BUB1 6 3.31E-02
B.
hsa04978 Mineral absorption MT1M, MT2A, CYBRD1, MT1E, MT1H,
MT1X, MT1G, MT1F
6 3.44E-04
hsa04918 Thyroid hormone synthesis SLC26A4, TG, HSP90B1, PAX8, TPO,
HSPA5, LRP2, TSHR, IYD
4 9.55E-04
hsa05200 Pathways in cancer FGFR2, BCR, EPAS1, PGF, RXRB,
GNAI1, RUNX1T1, FZD1, CDH1,
CDK6, KIT, CTNNA1, MMP2, CXCL12,
TCF7L1, AGTR1, FOS, HSP90B1, JUN,
PAX8, SOS2, LAMB1
2 5.48E-03
hsa04915 Estrogen signaling pathway HSPA1L, FOS, HSP90B1, GNAI1, JUN,
SOS2, HSPA1A, HSPA1B, MMP2
3 8.41E-03
hsa00600 Sphingolipid metabolism SPTLC1, SGMS2, SPTLC3, GALC,
PLPP3, ASAH1
4 1.17E-02
hsa04360 Axon guidance NRP1, LIMK2, SEMA6D, FYN, GNAI1,
PLXNA2, SEMA3D, UNC5C, CXCL12,
EPHA3
3 1.22E-02
hsa04141 Protein processing in
endoplasmic reticulum
HSPA1L, HSP90B1, ERO1B, UBE4B,
PDIA6, HSPA1A, HSPA1B, HSPA5,
CALR, MAN1C1, SEC62
2 2.68E-02
hsa04510 Focal adhesion ITGA9, CAV2, CAV1, CCND2, FYN,
PGF, JUN, SOS2, ITGB3, LAMB1, KDR,
MYL9
2 3.95E-02
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(b)
Symbol Description Feature
EGFR The epidermal growth factor receptor Hub protein
KIT KIT proto-oncogene receptor tyrosine kinase Hub protein
IRS1 Insulin receptor substrate 1 Hub protein
KDR kinase insert domain receptor Hub protein
BUB1B BUB1 mitotic checkpoint serine/threonine kinase B Hub protein
CDH1 Cadherin-1 Hub protein
BUB1 BUB1 mitotic checkpoint serine/threonine kinase Hub protein
TEK TEK receptor tyrosine kinase Hub protein
TPM2 tropomyosin 2 Hub protein
NR4A2 nuclear receptor subfamily 4 group A member 2 Hub protein
FOXC1 Forkhead Box C1 Reporter Transcription Factor
GATA2 GATA Binding Protein 2 Reporter Transcription Factor
YY1 YY1 Transcription Factor Reporter Transcription Factor
FOXL1 Forkhead Box L1 Reporter Transcription Factor
SPTLC1 Serine Palmitoyltransferase Long Chain Base Subunit 1 Reporter Transcription Factor
E2F1 E2F Transcription Factor 1 Reporter Transcription Factor
CD36 cluster of differentiation 36 Reporter Transcription Factor
SRF Serum Response Factor Reporter Transcription Factor
POU2F2 POU class 2 homeobox 2 Reporter Transcription Factor
EGR2 Early growth response 2 Reporter Transcription Factor
hsa-mir-548c-3p MicroRNA 548c Reporter microRNA
hsa-mir-335-5p MicroRNA 335 Reporter microRNA
hsa-mir-26b-5p MicroRNA 26b Reporter microRNA
hsa-mir-155-5p MicroRNA 155 Reporter microRNA
hsa-mir-124-3p MicroRNA 124 Reporter microRNA
hsa-mir-1-3p MicroRNA 1 Reporter microRNA
hsa-mir-16-5p MicroRNA 16 Reporter microRNA
hsa-mir-1-1 MicroRNA 1 Reporter microRNA
hsa-mir-192-5p MicroRNA 192 Reporter microRNA
hsa-mir-215-5p MicroRNA 215 Reporter microRNA
It was also observed that eight pathways were significantly over-represented. Mineral absorption,
thyroid hormone synthesis, pathways in cancer, oestrogen signalling, sphingolipid metabolism,
protein processing in the endoplasmic reticulum, axon guidance, and focal adhesion pathways (Table 1 (a))
were identified. These are associated with the DEGs expressed at lower levels in FTC lesions compared to
FTA. We then performed GO analysis using DAVID to obtain further insight into the molecular roles and
biological function of DEGs identified in this study. From this analysis, nine GO groups were associated
with DEGs that were more highly expressed in FTC (see Table 2 (a)). Reflecting their greater number,
the genes with lower expression in FTC compared to FTA were associated with 80 GO groups; the 10
most significant GO groups are presented in Table 2 (b). Fold enrichment, adjusted p-values, and genes
associated with these ontologies are also indicated.
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Table 2. (a) Gene ontologies associated with genes with higher expression in FTC. (b) Gene ontologies
associated with genes with lower expression in FTC compared to FTA. The 10 most significant biological
functional ontologies are indicated and are those associated with these significant genes. Fold enrichment,
adjusted p-values and genes associated with these ontologies are presented in these tables.
(a)
Go Term Pathway Genes in the Pathway Fold
Enrichment
Adjusted
p-Value
GO:0006636 unsaturated fatty acid biosynthetic
process
ELOVL4, SCD, ELOVL7 45 1.88E-03
GO:0007094 mitotic spindle assembly checkpoint MAD2L1, BUB1, BUB1B 33 3.39E-03
GO:0045773 positive regulation of axon extension TNFRSF12A, MAP1B, FN1 24 6.83E-03
GO:0044772 mitotic cell cycle phase transition CDK1, CKS2 67 2.92E-02
GO:0046602 regulation of mitotic centrosome
separation
KIF11, NEK2 67 2.92E-02
GO:0021930 cerebellar granule cell precursor
proliferation
ATF5, RORA 45 4.35E-02
GO:0035999 tetrahydrofolate interconversion TYMS, SHMT2 45 4.35E-02
GO:0035338 long-chain fatty-acyl-CoA
biosynthetic process
ELOVL4, ELOVL7 45 4.35E-02
GO:0046777 protein autophosphorylation EGFR, NEK2, STK26, MELK 5 4.78E-02
(b)
Go Term Pathway Genes in the Pathway Fold
Enrichment
Adjusted
p-Value
GO:0045926 negative regulation of growth ING5, MT1M, MT2A, MT1E, MT1H, MT1X,
MT1G, MT1F
18 1.37E-07
GO:0071294 cellular response to zinc ion MT1M, MT2A, MT1E, MT1H, MT1X, MT1G,
MT1F
16 3.17E-06
GO:0006590 thyroid hormone generation DIO2, CPQ, FOXE1, TPO, DIO1, IYD 21 4.56E-06
GO:0001525 angiogenesis FGFR2, EMCN, CAV1, NRP1, ACVRL1,
EPAS1, PGF, MMP2, KDR, PKNOX1, CTGF,
ID1, JUN, MAPK14, TEK, SCR, RHOB,
CALCRL
3 1.89E-05
GO:0001938 positive regulation of endothelial
cell proliferation
CAV2, NRP1, ACVRL1, PGF, F3, JUN, TEK,
ITGB3, CXCL12, KDR
6 2.97E-05
GO:0000122 negative regulation of transcription
from RNA polymerase II promoter
FGFR2, GLIS3, TSHZ3, ZMYND11, CAV1,
TFCP2L1, ZNF366, PRDM16, CALR, CBX7,
CITED2, MINA, TCF4, BHLHE41, NFIL3,
NR2F1, TXNIP, EGR1, NR4A2, TLE1, FOSB,
SNAI2, FOXP2, CD36, BTG2, ID1, SALL1,
FOXE1, LRP8, ID3, PRDM1, SMARCA2,
KLF4, NFIA, RERE, PEG3
2 3.16E-05
GO:0010628 positive regulation of gene
expression
CAV1, EPHX2, GJA1, TLE1, CDK6, KIT,
CALR, CITED2, ANK2, GSN, CTGF,
ID1, MAPK14, CYP26B1, NTRK2, RGCC,
PRDM1, NFIL3, KLF4
3 4.33E-05
GO:0030198 extracellular matrix organization B4GALT1, FBN1, OLFML2A, CDH1, ITGB3,
KDR, CSGALNACT1, SMOC2, ITGA9,
TNFRSF11B, COL9A3, ERO1B, FBLN5,
JAM2, LAMB1, CYR61
4 5.55E-05
GO:0043434 response to peptide hormone BTG2, GNAI1, CTGF, TEK, ANXA1, GJA1,
CXCL12, IRS1
8 6.31E-05
GO:0071276 cellular response to cadmium ion MT1E, MT1H, MT1X, MT1G, MT1F 13 5.36E-04
3.2.1. Proteomic Signatures: Hub Target Proteins from PPI Analysis
A PPI network was constructed using the DEGs identified in this study (Figure 2A) by using the
STRING package. Topological analyses using STRING and further analysis by Cytoscape’s Cyto-Hubba
plugin identified the most significant hub proteins, which were identified as gene products of TOP2A,
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JUN, EGFR, CDK1, FOS, CDKN3, EZH2, TYMS, PBK, CDH1, UBE2C, and CCNB2. The simplified PPI
network for the most significant hub genes was constructed by using Cyto-Hubba plugin and is shown in
Figure 2B.
A. B.
Figure 2. (A) The protein-protein interaction network constructed using the DEGs identified in the FTC/FTA
comparison. (B) The protein-protein interaction(PPI) network identified in FTC/FTA dataset DEGs showing
the most significant hub genes on the periphery (red).
3.2.2. Enrichment Analysis of the Modules Found in PPI of DEG
The PPI network was analysed by using MCODE plug-in in Cytoscape (version 3.5.1), and top three
modules were selected (Figure 3).
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A
C
C
B
Figure 3. Top three modules in the protein-protein interaction network of the DEGs in TC. The nodes
indicate the DEGs and the edges indicate the interactions between two genes. (A): Module-1; (B): Module-2;
(C): Module-3.
The enrichment analysis of the top three modules was analysed by using DAVID. Module 1
represented a set of biological process significantly enriched for ATP binding, cell division, and cell
proliferation; the associated enriched cellular components were the kinetochore, the condensed
chromosome kinetochore (both of which relate to cell division), and nucleoplasm and cytoplasm,
which are very general categories. Molecular functions significantly enriched in Module 1 included
chromatin binding and protein kinase activity (Table 3 (a)). Module 2 showed significantly enriched
biological process positive regulation of protein phosphorylation and protein autophosphorylation;
these significantly enriched cellular components included membrane raft, endosome, apical plasma
membrane, and focal adhesion. Molecular functions of Module 2 were enriched in protein tyrosine kinase
activity, enzyme binding, protein binding, and integrin binding (Table 3 (b)).
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Table 3. (a) The enrichment analysis of the subnetwork module-1 (b) The enrichment analysis of the
subnetworks module-2 and module-3.
(a) Subnetwork Module 1
Biological Process of Subnetwork Module 1
Term p Values Genes
ATP binding 1.00E-13 CDK1, KIF11, CCNB2, NEK2, BUB1, CENPF,
BUB1B, NDC80, ANLN, PBK, CEP55, ASPM
Cell division 1.28E-10 CDK1, KIF11, MAD2L1, CCNB2, NEK2, CKS2,
BUB1, CENPF, BUB1B, NDC80, UBE2C
Sister chromatidcohesion 6.92E-07 MAD2L1, BUB1, CENPF, BUB1B, NDC80, CENPK
Cell proliferation 1.76E-06 CDK1, TYMS, DLGAP5, CKS2, BUB1, CENPF,
BUB1B, MELK
mitotic spindle assembly checkpoint 4.64E-06 MAD2L1, BUB1, CENPF, BUB1B
chromosome segregation 4.68E-06 KIF11, NEK2, CENPF, NDC80, TOP2A
mitotic sister chromatidsegregation 9.32E-06 MAD2L1, NEK2, NUSAP1, NDC80
G2/M transition of mitotic cell cycle 7.46E-05 CDK1, CCNB2, NEK2, MELK, HMMR
negative regulation of ubiquitin-protein ligase
activity involved in mitotic cell cycle
2.20E-04 CDK1, MAD2L1, BUB1B, UBE2C
positive regulation of ubiquitin-protein ligase
activity involved in regulation of mitotic cell
cycle transition
2.69E-04 CDK1, MAD2L1, BUB1B, UBE2C
Cellular Component of Subnetwork Module 1
Kinetochore 1.39E-07 MAD2L1, NEK2, BUB1, CENPF, BUB1B, NDC80
Condensed chromosome kinetochore 1.99E-07 MAD2L1, NEK2, BUB1, BUB1B, NDC80, CENPK
Nucleoplasm 1.74E-05 CDK1, DTL, EZH2, KIAA0101, CENPF, ANLN,
UBE2C, CENPK, TYMS, CCNB2, FANCI, RRM2,
BUB1, TOP2A, UBE2T
Nucleus 3.38E-05 CDK1, DTL, NEK2, DLGAP5, EZH2, KIAA0101,
NUSAP1, CENPF, NDC80, PBK, CDKN3, CENPK,
TYMS, CCNB2, MAD2L1, RRM2, TOP2A, UBE2T,
ASPM, MELK
Midbody 4.30E-05 CDK1, NEK2, CENPF, CEP55, ASPM
Cytoplasm 9.43E-05 CDK1, KIF11, DTL, NEK2, DLGAP5, EZH2,
KIAA0101, NUSAP1, CENPF, UBE2C, CDKN3,
TYMS, FANCI, RRM2, BUB1, BUB1B, TOP2A,
UBE2T, ASPM
Centrosome 4.30E-04 CDK1, CCNB2, DTL, NEK2, CENPF, CEP55
Cytosol 5.65E-04 CDK1, KIF11, NEK2, CENPF, NDC80, UBE2C,
CENPK, HMMR, TYMS, CCNB2, MAD2L1, RRM2,
BUB1, BUB1B
Spindle pole 6.11E-04 KIF11, MAD2L1, NEK2, CENPF
Spindle microtubule 0.0020693 CDK1, KIF11, NUSAP1
Molecular Function of Subnetwork Module 1
Chromatin binding 3.63E-05 CDK1, EZH2, CKS2, KIAA0101, CENPF, TOP2A,
UBE2T
Protein kinaseactivity 2.78E-04 CDK1, NEK2, BUB1, BUB1B, PBK, MELK
protein serine/threoninekinaseactivity 3.44E-04 CDK1, NEK2, BUB1, BUB1B, PBK, MELK
ATP binding 4.78E-04 CDK1, KIF11, NEK2, BUB1, BUB1B, PBK, UBE2C,
TOP2A, UBE2T, MELK
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Table 3. Cont.
Protein binding 9.40E-04 CDK1, DTL, NEK2, DLGAP5, EZH2, KIAA0101,
NUSAP1, CENPF, NDC80, PBK, CEP55, UBE2C,
CENPK, CDKN3, HMMR, MAD2L1, CCNB2,
FANCI, RRM2, BUB1, CKS2, BUB1B, TOP2A,
MELK
Ubiquitinconjugating enzyme activity 4.70E-2 UBE2C, UBE2T
(b) Module 2 and Module 3
Biological Process of Module-2
Term p Values Genes
positive regulation of protein phosphorylation 6.67E-05 EGFR, CCND2, TEK, KDR
peptidyl-tyrosine phosphorylation 1.16E-04 EGFR, BCR, TEK, KDR
protein autophosphorylation 1.64E-04 EGFR, BCR, TEK, KDR
positive regulation of cell proliferation 1.65E-04 EGFR, CCND2, IRS1, KDR, FN1
positive regulation of ERK1 and ERK2 cascade 1.73E-04 EGFR, JUN, TEK, KDR
positive regulation of GTPase activity 3.47E-04 EGFR, BCR, JUN, TEK, IRS1
Angiogenesis 3.52E-04 JUN, TEK, KDR, FN1
positive regulation of fibroblast proliferation 5.48E-04 EGFR, JUN, FN1
positive regulation of endothelial cell
proliferation
8.94E-04 JUN, TEK, KDR
transmembrane receptor protein tyrosine
kinase signaling pathway
1.72E-03 EGFR, TEK, KDR
Molecular Function of Subnetwork Module-2
protein tyrosine kinase activity 5.51E-05 EGFR, BCR, TEK, KDR
transmembrane receptor protein tyrosine
kinase activity
2.20E-04 EGFR, TEK, KDR
enzyme binding 8.24E-04 EGFR, BCR, JUN, WWOX
protein binding 1.45E-03 EGFR, BCR, CCND2, JUN, TEK, CDH1, TCF4, IRS1,
WWOX, KDR, FN1
integrin binding 1.67E-03 EGFR, KDR, FN1
Ras guanyl-nucleotide exchange factor activity 2.00E-03 EGFR, TEK, IRS1
receptor signaling protein tyrosine kinase
activity
5.91E-03 EGFR, KDR
identical protein binding 8.26E-03 EGFR, JUN, TCF4, FN1
growth factor binding 1.59E-02 TEK, KDR
chromatin binding 2.13E-02 EGFR, JUN, TCF4
Cellular Component of Subnetwork Module-2
membrane raft 6.54E-03 EGFR, TEK, KDR
endosome 7.76E-03 EGFR, CDH1, KDR
apical plasma membrane 1.27E-02 EGFR, TEK, FN1
focal adhesion 2.22E-02 EGFR, TEK, CDH1
cell junction 3.00E-02 BCR, CDH1, KDR
microvillus 3.39E-02 TEK, WWOX
Biological Process of Subnetwork Module-3
protein ubiquitination 3.82E-05 SH3RF1, LMO7, FBXO32, FBXO9
Molecular Function of Subnetwork Module-3
ubiquitin ligase complex 2.07E-04 RNF144B, LMO7, FBXO9
SCF ubiquitin ligase complex 1.09E-02 FBXO32, FBXO9
Cellular Component of Subnetwork Module-3
ubiquitin-protein transferase activity 2.89E-05 RNF144B, LMO7, FBXO32, FBXO9
zinc ion binding 2.62E-02 SH3RF1, RNF144B, LMO7
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Module 3’s gene ontology annotation showed a significant enrichment for protein ubiquitination,
with significantly enriched cellular components being ubiquitin ligase complex and SCF ubiquitin ligase
complex, which have involvement in proteosomal and autophagy functions. Module 3’s molecular
functions showed significantly enrichment in ubiquitin-protein transferase activity and zinc ion binding
(Table 3 (b)). It is important to note that pathway enrichment analyses found Modules 1 and 2 were
significantly enriched in protein binding pathways, which was not seen in Module 3 (Table 3 (b)).
3.3. Regulatory Signatures: TFs and miRNAs Affecting DEG Transcript Levels
3.3.1. Transcriptional Regulatory Network Construction and TF Enrichment Analysis
The construction of reporter TFs and DEGs interaction network by NetworkAnalyst revealed a number
of potentially important TFs selected by the topological analysis using a dual metric approach involving
degree and betweenness (Figure 4). The top 10 ranked TFs with the highest degree and betweenness
centrality included FOXC1, GATA2, YY1, FOXL1, E2F1, NFIC, SRF, TFAP2A, HINFP, and CREB1.
Pathway enrichment analysis of the TFs that differ between FTC and FTA and DEGs mainly identified
as statistically significant, a number of relevant pathways which included transcriptional misregulation
in cancer, acute myeloid leukaemia, pathways in cancer, thyroid cancer, cell cycle, dorso-ventral axis
formation, arrhythmogenic right ventricular cardiomyopathy (ARVC), cocaine addiction, and prostate
cancer pathways (Table 4 (b)).
Figure 4. Construction of regulatory networks of TF-DEG interactions. Red nodes indicate up-regulation
and green nodes represent down-regulated DEGs.
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3.3.2. miRNA Regulatory Network Construction and Enrichment Analysis of miRNA
We constructed TC DEG-miRNA interactions networks using NetworkAnalyst (Figure 5).
By topological analysis, the top 10 ranked miRNAs by highest degree and betweenness centrality were
selected, which included hsa-mir-335-5p, hsa-mir-26b-5p, hsa-mir-124-3p, hsa-mir-16-5p, hsa-mir-192-5p,
hsa-mir-1-3p, hsa-mir-17-5p, hsa-mir-92a-3p, hsa-mir-215-5p, and hsa-mir-20a-5p. The analysis indicates
that these are miRNAs having the highest potential to regulate levels of the DEG transcripts differently
in FTC and FTA. The pathway enrichment analysis of the miRNA associated DEGs networks identified
the p53 signalling pathway, dorso-ventral axis formation, pertussis, adherens junction, thyroid cancer,
pathways in cancer, focal adhesion, sphingolipid metabolism, PPAR signalling pathway, and the
ECM-receptor interaction signalling system as statistically significant (Table 4 (a))
Figure 5. Construction of regulatory networks of the DEGs-miRNAs interaction. Red nodes indicate
up-regulation and green nodes represent down-regulated DEGs.
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Table 4. (a) Top 10 KEGG pathway in genes of micro-RNAs and differentially expressed genes interaction
networks (b) Top 10 KEGG pathway in genes of TFs and differentially expressed genes interaction networks
(a)
Pathway Total Expected Hits p-Value
Endocytosis 101 0.906 4 1.22E-02
PPAR signaling pathway 64 0.574 3 1.92E-02
Hypertrophic cardiomyopathy(HCM) 25 0.224 2 2.07E-02
Complement and coagulation cascades 67 0.601 3 2.16E-02
Cytokine-cytokine receptor interaction 253 2.27 6 2.40E-02
Adherens junction 70 0.628 3 2.43E-02
Thyroid cancer 28 0.251 2 2.56E-02
Glycine, serine and threonine metabolism 33 0.296 2 3.48E-02
Tyrosine metabolism 33 0.296 2 3.48E-02
Pathways in cancer 310 2.78 6 5.62E-02
(b)
Pathway Total Expected Hits p-Value
Pathways in cancer 310 5.37 20 1.66E-07
Chronic myeloid leukemia 73 1.26 8 3.07E-05
MAPK signaling pathway 265 4.59 15 3.67E-05
Maturity onset diabetes of the young 24 0.415 5 4.50E-05
Pertussis 52 0.9 6 2.41E-04
Transcriptional misregulation in cancer 19 0.329 4 2.65E-04
Acute myeloid leukemia 57 0.987 6 4.00E-04
HTLV-I infection 199 3.44 11 5.53E-04
Prostate cancer 87 1.51 7 6.87E-04
Thyroid cancer 28 0.485 4 1.24E-03
4. Discussion
To clarify the molecular mechanisms underlying the pathological features (especially malignancy
potential) that distinguish malignant and benign thyroid lesions, we examined differential gene expression
between FTC and FTA. Such a comparison is likely to be more informative than making such a comparison
of malignant and normal tissues, which would contain many more differences that relate to neoplastic
cell development. In addition, the lesions contain significant non-neoplastic cell components (such
as mesenchymally-derived and endothelial cells) that are also likely to differ markedly from those of
normal tissue.
The DEGs identified from the FTC/FTA comparison were used to identify possible regulatory
patterns, key molecular pathways, and protein-protein interactions among these pathway gene products.
Such an analytical approach can be used to find molecular signatures that may serve either as potential
therapeutic targets or as biomarkers to differentially diagnose or identify FTC. As did the original study by
Wojtas et al. [8], we identified significantly altered genes that may be candidate biomarkers that distinguish
FTC. However, another important use of such data (and our main focus here) is to identify and characterise
biological functions associated with these genes that may give insights into the biology and behaviour of
FTC lesions themselves. Wang et al. [36] examined on normal tissue vs. FTC and normal tissue vs. FTA
in the microarray dataset accession number GSE27155. They identified some important pathways that
included drug metabolism cytochrome p450, viral carcinogenesis, tyrosine metabolism, cytokine-cytokine
receptor interaction, and cocaine Addition as significant pathways distinguishing normal from FTC tissue.
Our analysis of the FTA vs. FTC tissue data found several important pathways, as described in the above
results section. However, there were no pathways that we identified (in our FTC/FCA comparison) which
were also seen in the studies comparing FTC to normal tissues. This almost certainly reflects the fact that
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a tumour has very different cellular profiles compared to normal tissue (e.g., infiltrating leukocytes and
stromal cells) so in this circumstance, where we want to better understand the behaviour of the tumour,
it is be better to compare with a benign or non-aggressive tumour such as FTA. Our study thus identified
a number of important pathways that were differentially expressed in FTC, some of which would be
expected by the malignant profile of FTC compared to FTA. For example, the p53 signalling pathway
plays an important role in cancer cell apoptosis and DNA repair by causing cycle arrest in response to
DNA damage [37], and has been previously implicated in thyroid cancers [38]. Cell cycle progression
is regulated and facilitated by cyclin-dependent kinases that are activated by cyclins such as cyclin D1.
Indeed, cyclin D1 levels can influence tumour progression, and may have prognostic significance in
FTC [39]. Related to this, it has also been reported that the one-carbon metabolism pathway is actively
involved in cancer progression, probably due to its involvement in nucleotide synthesis [40]. We have
summarised the significant GO groups associated with the DEGs, as shown in Table 2 .
PPI network reconstruction and the analysis of reconstructed PPI network represent a powerful
approach for understanding disease mechanisms, so to construct a PPI network for the DEGs in our study,
we combined results of statistical analyses with the protein interactome network. To identify potential hub
proteins, topological analysis strategies were employed. This method identified 12 hub genes (Table 1 (b)),
including a number of genes commonly associated with cancers (including thyroid cancers), such as EGRF,
JUN, FOS, CDK1, and other cyclin pathway genes, E-cadherin (CDH1) and E2F1. The hub protein EGFR is
linked to growth in many types of cancer, and cardiovascular diseases, and has been previously linked
to thyroid cancers [41]. JUN and FOS are best characterised as subunits of the AP-1 transcription factor
that has a crucial role in many types of cell differentiation and inflammation processes [42]. GO databases
also delineated particular roles for JUN in angiogenesis and the regulation of endothelial cell proliferation,
both of which have central roles in metastasis and invasion (Table 2 (b)). CDK1 is an important cell cycle
regulator and is involved in breast, lung, and ovary carcinomas [43]. CDK1 overexpression has been
documented in lung cancer, lymphoma, and advanced melanoma, while loss of cytoplasmic CDK1 predicts
poor patient survival and may confer chemotherapeutic resistance in the latter [44]. Cyclin B1 (in the same
family as CDK1) overexpression and/or mislocalisation has been described in several primary cancers,
including thyroid carcinoma and colon, gastric, prostate, breast, and non small-cell lung cancers [44].
It is also actively involved in mitotic cell cycle phase transition (Table 2 (a)). CDKN3 encodes a cyclin
inhibitor (regulating cell cycle) and has been described as being overexpressed in lung adenocarcinoma
(ADC), squamous cell carcinoma (SCC), hepatocellular carcinoma, cervical cancer, and epithelial ovarian
cancer [45]. Over-expression of EZH2 is frequently observed in many cancer types [46].
TYMS expression is also associated with the risk of development of epithelial cancers and lymphoma
cancer [47]. In addition, in hereditary diffuse gastric cancer (HDGC), the hub gene CDH1 mutations are
connected with an increased incidence of lobular carcinoma of the breast, and possibly, prostate cancer
and colorectal carcinoma [48]. This gene is also involved in extracellular matrix organisation (Table 2 (b)).
Hub gene CCNB2 is known to be underexpressed in thyroid cell tumours [49]. We found that CDK1 and
CCNB2 hubs genes were actively associated with the p53 signalling, progesterone-mediated oocyte
maturation, and cell cycle pathways. The hub gene TYMS is also involved in one carbon pool by
folate pathway; FOS, JUN, and CDH1 genes are involved in pathways in cancer; and JUN and FOS
genes are involved in the oestrogen signalling pathway. A number of other hub genes have been
described as associated with malignant thyroid cancers, including EXH2, UBCH10,TFAP2A, TOP2A,
and SRF [50–54]. By considering the possible roles of these hub proteins in pathogenesis of FTC and other
related diseases, new roles for these proteins may be identified. In addition to the above-mentioned hub
genes, we also identified a number of factors not previously noted as having a role in FTC or thyroid
cancers, including UBA52, GATA2, FOXL1, and NFIC.
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As the regulation of gene expression is controlled by TFs and miRNAs at post-transcriptional
and/or transcriptional levels, changes in these molecules may provide crucial information regarding
the dysregulation of gene expression in FTC. Thus, we investigated TFs and their relationship to DEGs
in these tumours, including FOXC1. One prior study found that FOXC1 is strongly associated with
thyroid cancers [55]. The overexpression of YY1 in differentiated thyroid cancers has also been noted [56].
The pathway analysis of these TFs showed statistically significance in FTC. From the DEGs, a miRNA
interaction network of miRNAs (Table 1 (b)) was also identified and analysed. Our pathway analysis of
these miRNA also showed statistically significant relationships with FTC. Notably, the target DEGs of
these miRNAs and TFs included the p53 signalling pathway, PPAR signalling pathway, dorso-ventral axis
formation pathway, focal adhesion pathway (Table 4 (a)), pathways in cancer, transcriptional misregulation
in cancer, and thyroid cancer pathway. The miRNA species we identified that have previously
been shown to have a role in thyroid cancer, including hsa-mir-335-5p, hsa-124-3p, hsa-mir-17-5p,
and hsa-mir-20a-5p [57–60]. However, six other miRNAs we identified have not previously been associated
with thyroid lesions. miRNA species have wide ranging effects on gene expression which are indirect,
so further analysis for these are needed.
We analysed the dataset originally generated by Wojtas et al., who used combined micro-array
methods and literature meta-analysis to achieve this to find markers to distinguish FTC and FTA. The gene
markers they identified included TFF3, CPQ (previously characterised FTC markers), PLVAP, and ACVRL1,
all genes expressed in the thyroid, although ACVR1 is an activin receptor with wide expression. These latter
genes were not identified by our analytical approach, but it should be noted that our study used very
different analytic tools, focussing on identifying pathways and on finding evidence for gene functions
using PPI and other resources. Our analytical approach was somewhat similar to that of Wang et al. [36]
who examined an older thyroid cancer dataset (GSE27155) containing 10 FTA, 14 FTC, and 4 normal
thyroid tissue samples plus those of other types of thyroid lesions. While we employed a number of
additional analytical tools (some developed previously by us), there were a number of significant genes
and pathways that were also found in the work by Wang et al. [36] where they compared FTC and FTA.
These notably included the AP-1 TF and its components (e.g., JUN and FOS), BCL2, factors relating to
DNA damage, and cyclin-related factors that regulate the cell cycle. As noted above, We identified no
genes that Wang et al. identified when comparing FTC and normal tissues. Recent studies by Shang et al.
and by Liang and Sun [61] examined datasets generated from papillary thyroid cancer lesions that were
compared with normal tissues. DEGs identified in these studies were analysed by methods related to our
approach [35]. However, unlike the Wang et al. study cited above, very few of the hub genes these studies
identified were found in our analysis, BCL2 being the main exception. This lack of concordance with the
FTC studies may reflect the different tumour types (and lower malignancy rates) represented by papillary
thyroid cancer, and it might be useful to compare all these datasets in further detail to determine how
these types of tumour differ. We also note that work by Pfeifer et al. [62] developed a classification using
gene expression data that considered only five genes, and this distinguished FTC from FTA with good
accuracy. They identified five genes (ELMO1, EMCN, ITIH5, KCNAB1, and SLCO2A1) as biomarkers.
However, it should be emphasised that the focus of our work and methodology is different (since we
studied pathway differences not gene classifiers), so not surprisingly, there were no significant genes
identified in common between our work and Pfeifer et al.
5. Conclusions
Our data-driven approach has uncovered a number of significant molecular mechanisms that may
underlie the pathogenic differences seen between FTC and FTA. In this study we used integrated
bioinformatic analyses to study gene expression profiles in FTC and FTA, and used this information
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to identify candidate hub proteins that could play significant roles in FTC development. Our results
included a number candidate genes and pathways that indicate the directions for future experimental
work needed to clarify the roles of these cellular factors. This study identified gene networks that advance
our understanding of FTC pathogenesis and indicates new avenues to develop therapies for FTC.
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